keyword
MENU ▼
Read by QxMD icon Read
search

Pseudoprogression

keyword
https://www.readbyqxmd.com/read/28296759/the-diagnostic-performance-of-perfusion-mri-for-differentiating-glioma-recurrence-from-pseudoprogression-a-meta-analysis
#1
Bing Wan, Siqi Wang, Mengqi Tu, Bo Wu, Ping Han, Haibo Xu
BACKGROUND: The purpose of this meta-analysis was to evaluate the diagnostic accuracy of perfusion magnetic resonance imaging (MRI) as a method for differentiating glioma recurrence from pseudoprogression. METHODS: The PubMed, Embase, Cochrane Library, and Chinese Biomedical databases were searched comprehensively for relevant studies up to August 3, 2016 according to specific inclusion and exclusion criteria. The quality of the included studies was assessed according to the quality assessment of diagnostic accuracy studies (QUADAS-2)...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28282372/automated-fluorescent-miscroscopic-image-analysis-of-ptbp1-expression-in-glioma
#2
Behiye Kaya, Evgin Goceri, Aline Becker, Brad Elder, Vinay Puduvalli, Jessica Winter, Metin Gurcan, José Javier Otero
Multiplexed immunofluorescent testing has not entered into diagnostic neuropathology due to the presence of several technical barriers, amongst which includes autofluorescence. This study presents the implementation of a methodology capable of overcoming the visual challenges of fluorescent microscopy for diagnostic neuropathology by using automated digital image analysis, with long term goal of providing unbiased quantitative analyses of multiplexed biomarkers for solid tissue neuropathology. In this study, we validated PTBP1, a putative biomarker for glioma, and tested the extent to which immunofluorescent microscopy combined with automated and unbiased image analysis would permit the utility of PTBP1 as a biomarker to distinguish diagnostically challenging surgical biopsies...
2017: PloS One
https://www.readbyqxmd.com/read/28274394/pseudoprogression-of-a-spinal-metastasis-after-stereotactic-ablative-body-radiation-therapy-and-immune-checkpoint-therapy
#3
Sachin R Jhawar, Ann W Silk, Sharad Goyal
No abstract text is available yet for this article.
March 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28176884/impact-of-including-peritumoral-edema-in-radiotherapy-target-volume-on-patterns-of-failure-in-glioblastoma-following-temozolomide-based-chemoradiotherapy
#4
Seo Hee Choi, Jun Won Kim, Jee Suk Chang, Jae Ho Cho, Se Hoon Kim, Jong Hee Chang, Chang-Ok Suh
We assessed the impact of including peritumoral edema in radiotherapy volumes on recurrence patterns among glioblastoma multiforme (GBM) patients treated with standard chemoradiotherapy (CRT). We analyzed 167 patients with histologically confirmed GBM who received temozolomide (TMZ)-based CRT between May 2006 and November 2012. The study cohort was divided into edema (+) (n = 130) and edema (-) (n = 37) groups, according to whether the entire peritumoral edema was included. At a median follow-up of 20 months (range, 2-99 months), 118 patients (71%) experienced progression/recurrence (infield: 69%; marginal: 26%; outfield: 16%; CSF seeding: 12%)...
February 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28175467/219%C3%A2-liquid-biopsy-can-distinguish-recurrent-glioblastomas-from-pseudoprogression-and-radiation-necrosis-after-concurrent-radiochemotherapy
#5
Andrew E Sloan, David Soler, Anne B Young, Kelvin D Cooper, Thomas McCormic
No abstract text is available yet for this article.
August 1, 2016: Neurosurgery
https://www.readbyqxmd.com/read/28143434/combination-of-ivim-dwi-and-3d-asl-for-differentiating-true-progression-from-pseudoprogression-of-glioblastoma-multiforme-after-concurrent-chemoradiotherapy-study-protocol-of-a-prospective-diagnostic-trial
#6
Zhi-Cheng Liu, Lin-Feng Yan, Yu-Chuan Hu, Ying-Zhi Sun, Qiang Tian, Hai-Yan Nan, Ying Yu, Qian Sun, Wen Wang, Guang-Bin Cui
BACKGROUND: Standard therapy for Glioblastoma multiforme (GBM) involves maximal safe tumor resection followed with radiotherapy and concurrent adjuvant temozolomide. About 20 to 30% patients undergoing their first post-radiation MRI show increased contrast enhancement which eventually recovers without any new treatment. This phenomenon is referred to as pseudoprogression. Differentiating tumor progression from pseudoprogression is critical for determining tumor treatment, yet this capacity remains a challenge for conventional magnetic resonance imaging (MRI)...
February 1, 2017: BMC Medical Imaging
https://www.readbyqxmd.com/read/28121940/not-only-for-melanoma-subcutaneous-pseudoprogression-in-lung-squamous-cell-carcinoma-treated-with-nivolumab-a-case-report
#7
Michal Sarfaty, Assaf Moore, Elizabeth Dudnik, Nir Peled
RATIONALE: Pseudoprogression, that is, initial tumor growth followed by subsequent tumor regression, has been well described for immunomodulation therapy in melanoma patients. This phenomenon is not well defined in lung cancer. Nivolumab, an anti-PD-1 monoclonal antibody, was recently approved for nonsmall cell lung cancer (NSCLC) as a second-line therapy. PATIENT CONCERNS AND DIAGNOSIS: We present a patient with squamous NSCLC, suffering from multiple bone and subcutaneous metastases...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28108885/modified-criteria-for-radiographic-response-assessment-in-glioblastoma-clinical-trials
#8
REVIEW
Benjamin M Ellingson, Patrick Y Wen, Timothy F Cloughesy
Radiographic endpoints including response and progression are important for the evaluation of new glioblastoma therapies. The current RANO criteria was developed to overcome many of the challenges identified with previous guidelines for response assessment, however, significant challenges and limitations remain. The current recommendations build on the strengths of the current RANO criteria, while addressing many of these limitations. Modifications to the current RANO criteria include suggestions for volumetric response evaluation, use contrast enhanced T1 subtraction maps to increase lesion conspicuity, removal of qualitative non-enhancing tumor assessment requirements, use of the post-radiation time point as the baseline for newly diagnosed glioblastoma response assessment, and "treatment-agnostic" response assessment rubrics for identifying pseudoprogression, pseudoresponse, and a confirmed durable response in newly diagnosed and recurrent glioblastoma trials...
January 20, 2017: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://www.readbyqxmd.com/read/28066810/dynamic-susceptibility-contrast-mri-quantification-software-tool-development-and-evaluation
#9
Panagiotis Korfiatis, Timothy L Kline, Zachary S Kelm, Rickey E Carter, Leland S Hu, Bradley J Erickson
Relative cerebral blood volume (rCBV) is a magnetic resonance imaging biomarker that is used to differentiate progression from pseudoprogression in patients with glioblastoma multiforme, the most common primary brain tumor. However, calculated rCBV depends considerably on the software used. Automating all steps required for rCBV calculation is important, as user interaction can lead to increased variability and possible inaccuracies in clinical decision-making. Here, we present an automated tool for computing rCBV from dynamic susceptibility contrast-magnetic resonance imaging that includes leakage correction...
December 2016: Tomography: a Journal for Imaging Research
https://www.readbyqxmd.com/read/28061488/the-use-of-mr-perfusion-imaging-in-the-evaluation-of-tumor-progression-in-gliomas
#10
Brian Snelling, Ashish H Shah, Simon Buttrick, Ronald Benveniste
OBJECTIVE: Diagnosing tumor progression and pseudoprogression remains challenging for many clinicians. Accurate recognition of these findings remains paramount given necessity of prompt treatment. However, no consensus has been reached on the optimal technique to discriminate tumor progression. We sought to investigate the role of magnetic resonance perfusion (MRP) to evaluate tumor progression in glioma patients. METHODS: An institutional retrospective review of glioma patients undergoing MRP with concurrent clinical follow up visit was performed...
January 1, 2017: Journal of Korean Neurosurgical Society
https://www.readbyqxmd.com/read/28030820/unsupervised-consensus-cluster-analysis-of-18f-fluoroethyl-l-tyrosine-positron-emission-tomography-identified-textural-features-for-the-diagnosis-of-pseudoprogression-in-high-grade-glioma
#11
Sied Kebir, Zain Khurshid, Florian C Gaertner, Markus Essler, Elke Hattingen, Rolf Fimmers, Björn Scheffler, Ulrich Herrlinger, Ralph A Bundschuh, Martin Glas
RATIONALE: Timely detection of pseudoprogression (PSP) is crucial for the management of patients with high-grade glioma (HGG) but remains difficult. Textural features of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (FET-PET) mirror tumor uptake heterogeneity; some of them may be associated with tumor progression. METHODS: Fourteen patients with HGG and suspected of PSP underwent FET-PET imaging. A set of 19 conventional and textural FET-PET features were evaluated and subjected to unsupervised consensus clustering...
January 31, 2017: Oncotarget
https://www.readbyqxmd.com/read/28018599/immune-related-response-assessment-during-pd-1-inhibitor-therapy-in-advanced-non-small-cell-lung-cancer-patients
#12
Mizuki Nishino, Nikhil H Ramaiya, Emily S Chambers, Anika E Adeni, Hiroto Hatabu, Pasi A Jänne, F Stephen Hodi, Mark M Awad
BACKGROUND: Tumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-cell lung cancer (NSCLC) patients treated with nivolumab monotherapy in the clinical setting have not been previously described with a direct comparison with the assessments according to the conventional RECIST1.1. METHODS: Fifty-six advanced NSCLC patients treated with nivolumab monotherapy after its Food and Drug Administration (FDA) approval were retrospectively studied...
2016: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/27998280/misleading-early-blood-volume-changes-obtained-using-ferumoxytol-based-magnetic-resonance-imaging-perfusion-in-high-grade-glial-neoplasms-treated-with-bevacizumab
#13
Joao Prola Netto, Daniel Schwartz, Csanad Varallyay, Rongwei Fu, Bronwyn Hamilton, Edward A Neuwelt
BACKGROUND: Neovascularization, a distinguishing trait of high-grade glioma, is a target for anti-angiogenic treatment with bevacizumab (BEV). This study sought to use ferumoxytol-based dynamic susceptibility contrast magnetic resonance imaging (MRI) to clarify perfusion and relative blood volume (rCBV) changes in glioma treated with BEV and to determine potential impact on clinical management. METHODS: 16 high grade glioma patients who received BEV following post-chemoradiation radiographic or clinical progression were included...
December 20, 2016: Fluids and Barriers of the CNS
https://www.readbyqxmd.com/read/27987588/report-of-two-cases-of-pseudoprogression-in-patients-with-non-small-cell-lung-cancer-treated-with-nivolumab-including-histological-analysis-of-one-case-after-tumor-regression
#14
Junko Tanizaki, Hidetoshi Hayashi, Masatomo Kimura, Kaoru Tanaka, Masayuki Takeda, Shigeki Shimizu, Akihiko Ito, Kazuhiko Nakagawa
The recent approval of nivolumab and other immune-checkpoint inhibitors for the treatment of certain solid tumors including non-small cell lung cancer (NSCLC) has transformed cancer therapy. However, it will be important to characterize effects of such agents not seen with classical cytotoxic drugs or other targeted therapeutics. We here report two cases of NSCLC showing so-called pseudoprogression during nivolumab treatment. In both cases, imaging assessment revealed that liver metastatic lesions initially progressed but subsequently shrank during continuous nivolumab administration, with treatment also resulting in a decline in serum levels of carcinoembryonic antigen...
December 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27895919/recurrent-pleural-effusions-and-cardiac-tamponade-as-possible-manifestations-of-pseudoprogression-associated-with-nivolumab-therapy-a-report-of-two-cases
#15
Bhaskar C Kolla, Manish R Patel
BACKGROUND: Checkpoint inhibitors are a class of agents that employ host's adaptive immune defenses in fighting cancer. With many new indications and several ongoing clinical trials in a variety of malignancies, the usage of these agents is set to increase significantly. One of the key challenges patients and physicians face while using these drugs is with the appropriate assessment of response to therapy. CASE PRESENTATION: We are reporting two patients with lung cancer who were treated with nivolumab and experienced rapidly accumulating recurrent pleural effusions requiring multiple thoracenteses (6 and 4 times each for patient 1 and 2 respectively) with in the first few weeks of initiation of therapy and also developed pericardial effusion with cardiac tamponade requiring pericardiocentesis...
2016: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/27889021/neuroimaging-of-peptide-based-vaccine-therapy-in-pediatric-brain-tumors-initial-experience
#16
REVIEW
Andre D Furtado, Rafael Ceschin, Stefan Blüml, Gary Mason, Regina I Jakacki, Hideho Okada, Ian F Pollack, Ashok Panigrahy
The potential benefits of peptide-based immunotherapy for pediatric brain tumors are under investigation. Treatment-related heterogeneity has resulted in radiographic challenges, including pseudoprogression. Conventional MR imaging has limitations in assessment of different forms of treatment-related heterogeneity, particularly regarding distinguishing true tumor progression from efficacious treatment responses. Advanced neuroimaging techniques, including diffusion magnetic resonance (MR), perfusion MR, and MR spectroscopy, may add value in the assessment of treatment-related heterogeneity...
February 2017: Neuroimaging Clinics of North America
https://www.readbyqxmd.com/read/27885955/editorial-vestibular-schwannoma-radiosurgery-progression-or-pseudoprogression
#17
Jean Régis, Christine Delsanti, Pierre-Hugues Roche
No abstract text is available yet for this article.
November 25, 2016: Journal of Neurosurgery
https://www.readbyqxmd.com/read/27873302/ultrasonographic-findings-can-identify-pseudoprogression-under-nivolumab-therapy
#18
K Imafuku, H Hata, S Kitamura, T Yanagi, H Shimizu
'Pseudoprogression' is often seen in patients with melanomas who are treated with immune-checkpoint inhibitors such as nivolumab or ipilimumab. We sometimes evaluate metastatic lesions by imaging tests such as CT or PET-CT. 'Pseudoprogression' usually occurs upon the initial administration, which may make it difficult for the physician to determine the disease condition. In our two cases of metastatic melanoma treated with nivolumab (anti-PD-1 antibody), we examined the ultrasonography (US) of target lesions that could be accessed from the body surface, such as those of the regional lymph node or subcutaneous metastasis...
November 22, 2016: British Journal of Dermatology
https://www.readbyqxmd.com/read/27864299/challenges-in-the-use-of-immunotherapy-in-metastatic-melanoma
#19
Ashley Tran, Shayna Sarosiek, Naomi Y Ko
A 65-year-old man with metastatic melanoma was started on immunotherapy, switched to alternative targeted therapy and developed disseminated intravascular coagulation. This case underscores the complexity of interpreting and managing side effects of novel therapies in cancer care, identification of progression versus pseudoprogression and challenges in sequencing treatments in metastatic melanoma.
November 18, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27822695/the-treatment-of-melanoma-brain-metastases
#20
REVIEW
Nour Kibbi, Harriet Kluger
Melanoma is the malignancy with the highest rate of dissemination to the central nervous system once it metastasizes. Until recently, the prognosis of patients with melanoma brain metastases (MBM) was poor. In recent years, however, the prognosis has improved due to high-resolution imaging that facilitates early detection of small asymptomatic brain metastases and early intervention with local modalities such as stereotactic radiosurgery. More recently, a number of systemic therapies have been approved by the Food and Drug Administration for metastatic melanoma, resulting in improved survival for many MBM patients...
December 2016: Current Oncology Reports
keyword
keyword
12545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"